Pharmaceutical manufacturers with United States Food and Drug Administration-approved prescription drugs sold in or into Texas with any prescription drugs costing $100 or more for a one-month supply as outlined in Chapter 441, §441.002 (c) are required to submit a manufacturer activity report.
The manufacturer activity report is a list of every drug that has lost patent exclusivity and/or received U.S. FDA approval in the last three calendar years. It also includes the manufacturer’s R&D costs.
Last updated: 08/14/2020
| Manufacturer | Change type | Change year | NDC 11 | Trade Name | Generic Name | R and D cost |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc. | A | 2016 | 63090034030 | NUPLAZID | pimavanserin | $240,385,000 |
| ACADIA Pharmaceuticals Inc. | A | 2016 | 63090010030 | NUPLAZID | pimavanserin | $240,385,000 |
| B. Braun Medical Inc. | A | 2019 | 264937988 | Bupivacaine HCl 0.75% in Dextrose 8.25% Injection USP | Bupivacaine HCl 0.75% in Dextrose 8.25% Injection USP | $55,260,000 |
| B. Braun Medical Inc. | A | 2019 | 264450005 | Plenamine | 15% Amino Acids Injection | $55,260,000 |
| B. Braun Medical Inc. | A | 2018 | 264937688 | 1% Lidocaine Injection | 1% Lidocaine Injection | $55,260,000 |
| B. Braun Medical Inc. | A | 2018 | 264780090 | 0.9% Sodium Chloride Injection USP | 0.9% Sodium Chloride Injection USP | $55,260,000 |
| B. Braun Medical Inc. | A | 2018 | 264780001 | 0.9% Sodium Chloride Injection USP | 0.9% Sodium Chloride Injection USP | $55,260,000 |
| B. Braun Medical Inc. | A | 2018 | 264450000 | Plenamine | 15% Amino Acids Injection | $55,260,000 |
| Endo Pharmaceuticals | L | 2019 | 52244003060 | Striant | testosterone buccal system | $130,732,000 |
| Endo Pharmaceuticals | L | 2018 | 63481018316 | FORTESTA | testosterone | $130,732,000 |
| ENDO PHARMACEUTICALS INC | A | 2020 | Doxepin | Doxepin | $130,732,000 | |
| ENDO PHARMACEUTICALS INC | A | 2020 | Naloxone Hydrochloride | Naloxone Hydrochloride | $130,732,000 | |
| ENDO PHARMACEUTICALS INC | A | 2020 | 73611030010 | Qwo | collagenase clostridium histolyticum aaes | $130,732,000 |
| ENDO PHARMACEUTICALS INC | A | 2020 | 73611030005 | Qwo | collagenase clostridium histolyticum aaes | $130,732,000 |
| ENDO PHARMACEUTICALS INC | A | 2020 | 00254101019 | Diazoxide | Diazoxide | $130,732,000 |